# Moderna

mRNA医药先驱——Spikevax新冠疫苗及扩展中的流感、HIV和肿瘤管线；自有mRNA合成-LNP-制造平台；营收32亿美元；NASDAQ: MRNA。

Source: https://cn.bioecon.ru/companies/moderna/
Updated: 2026-06-19

- 国家: United States
- 营收: $3.2B
- 员工: ~5,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2026年通过可转换债券发行募集$26亿 | https://www.biopharmadive.com/news/fda-covid-vaccines-moderna-generate-profound-bixlenvo/828929/ |
| 营收 | 2025年$19亿 | https://www.nasdaq.com/press-release/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |
| 营收 | 2026年第二季度$1.45亿 | https://last10k.com/sec-filings/mrna/0001682852-26-000150.htm, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm |
| 生产基地 | 马萨诸塞州Norwood（Moderna技术中心）；马萨诸塞州Marlborough；以及英国、加拿大和澳大利亚的设施 | https://www.modernatx.com/en-US/about-us/our-story, https://www.nasdaq.com/press-release/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |
| 员工人数 | 截至2025财年末4,700名员工 | https://financhle.com/company/MRNA/employees, https://tickerleague.com/companies/MRNA/employee-count |
| 监管批准 | Spikevax（COVID-19）、mNEXSPIKE（COVID-19）、mRESVIA（RSV）及mCOMBRIAX（流感+COVID联合疫苗，欧盟已批准） | https://www.biospace.com/press-releases/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines, https://www.fda.gov/vaccines-blood-biologics/spikevax, https://www.modernatx.com/en-US/about-us/our-story, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |

独立来源: biopharmadive.com, biospace.com, fda.gov, financhle.com, last10k.com, nasdaq.com, sec.gov, stocktitan.net, tickerleague.com

## 技术

- [mRNA 平台与 LNP 递送](https://cn.bioecon.ru/technology/mrna-platforms-lnp-delivery/)
- [药物与疫苗研发](https://cn.bioecon.ru/technology/drug-vaccine-development/)